AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Imagion Biosystems

0.025

0.000

Volume:990.38K

Turnover:24.76K

Market Cap:12.26M

PE:-1.46

High:0.025

Open:0.025

Low:0.025

Close:0.025

52wk High:0.055

52wk Low:0.011

Shares:490.59M

Float Shares:172.45M

Volume Ratio:0.45

T/O Rate:0.57%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.017

EPS(LYR):-0.046

ROE:-2804.87%

ROA:-83.89%

PB:-3.17

PE(LYR):-0.54

Loading ...

Overview Company News Filings

Imagion Biosystems Submits IND Application to FDA for MagSense HER2 Imaging Agent

Medical-Imaging Company Imagion Biosystems Lodges Ind With FDA for Phase 2 Trial of Magsense® Her2 Targeted Imaging Agent

THOMSON REUTERS

Imagion Biosystems Ltd - Enrollment for Phase 2 Trial Could Begin Q1 2026

THOMSON REUTERS

Imagion Biosystems Ltd-Appendix 4C and Quarterly Activities Report - September 2025

THOMSON REUTERS

Imagion Biosystems Completes Imaging Agent Production; Shares Rise 6%

MT Newswires Live

ASX Biggest Gainers

MT Newswires Live

ASX Runners of the Week: 333D, Imagion Biosciences, Zenith & Locksley

The West Australian

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IBX.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IBX.AU\",,,,,undefined,":{"symbol":"IBX.AU","market":"AU","secType":"STK","nameCN":"Imagion Biosystems","latestPrice":0.025,"timestamp":1770786720000,"preClose":0.025,"halted":0,"volume":990378,"delay":0,"changeRate":0,"nameEN":"Imagion Biosystems","floatShares":172453894,"shares":490590239,"eps":-0.017095,"marketStatus":"Not Yet Opened","change":0,"latestTime":"02-11 16:12:00 AEDT","open":0.025,"high":0.025,"low":0.025,"amount":24759,"amplitude":0,"askPrice":0.025,"askSize":458660,"bidPrice":0.024,"bidSize":859324,"shortable":3,"etf":0,"ttmEps":-0.017095,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1770850800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.025,"openAndCloseTimeList":[[1770764400000,1770786000000]],"volumeRatio":0.454018,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IBX.AU\",,,,,undefined,":{"symbol":"IBX.AU","floatShares":172453894,"roa":"-83.89%","roe":"-2804.87%","lyrEps":-0.045985,"volumeRatio":0.454018,"shares":490590239,"dividePrice":0,"high":0.025,"amplitude":0,"preClose":0.025,"low":0.025,"week52Low":0.011,"pbRate":"-3.17","psRate":"11.62","week52High":0.055,"institutionHeld":0,"latestPrice":0.025,"committee":0.303998,"eps":-0.017095,"divideRate":0,"volume":990378,"delay":0,"ttmEps":-0.017095,"open":0.025,"prevYearClose":0.025,"prevWeekClose":0.023,"prevMonthClose":0.024,"prevQuarterClose":0.025,"fiveDayClose":0.025,"twentyDayClose":0.03,"sixtyDayClose":0.022,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBX.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2023-11-16","symbol":"IBX.AU","defaultRemindTime":1700089200000,"type":"split","dateTimestamp":1700053200000,"forFactor":40,"toFactor":1,"ratio":40}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBX.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2608580538","title":"Imagion Biosystems Submits IND Application to FDA for MagSense HER2 Imaging Agent","url":"https://stock-news.laohu8.com/highlight/detail?id=2608580538","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608580538?lang=en_us&edition=fundamental","pubTime":"2026-02-04 00:30","pubTimestamp":1770136218,"startTime":"0","endTime":"0","summary":"Imagion Biosystems Ltd. has submitted an Investigational New Drug  application to the U.S. Food and Drug Administration  for its MagSense HER2 targeted imaging agent. The company plans to initiate a Phase 2 clinical trial to evaluate the imaging agent for detecting nodal metastases in HER2-positive breast cancer patients, pending FDA approval. Enrollment for the trial could begin as early as the first quarter of 2026, based on historical FDA review timelines. Imagion Biosystems has engaged all necessary strategic trial partners and is advancing logistical preparations in compliance with Good Clinical Practices.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Imagion Biosystems Ltd. published the original content used to generate this ne","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL3fhmTg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBX.AU","BK7007"],"gpt_icon":0},{"id":"2608805855","title":"Medical-Imaging Company Imagion Biosystems Lodges Ind With FDA for Phase 2 Trial of Magsense® Her2 Targeted Imaging Agent","url":"https://stock-news.laohu8.com/highlight/detail?id=2608805855","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608805855?lang=en_us&edition=fundamental","pubTime":"2026-02-04 00:30","pubTimestamp":1770136200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nTUA84DDZD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7007","IBX.AU"],"gpt_icon":0},{"id":"2608058008","title":"Imagion Biosystems Ltd - Enrollment for Phase 2 Trial Could Begin Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2608058008","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608058008?lang=en_us&edition=fundamental","pubTime":"2026-02-04 00:30","pubTimestamp":1770136200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nTUA84DDZD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBX.AU","BK7007"],"gpt_icon":0},{"id":"2577891057","title":"Imagion Biosystems Ltd-Appendix 4C and Quarterly Activities Report - September 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2577891057","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577891057?lang=en_us&edition=fundamental","pubTime":"2025-10-21 06:42","pubTimestamp":1761000173,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nTUE7SCWW1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBX.AU","BK7007"],"gpt_icon":0},{"id":"2573939890","title":"Imagion Biosystems Completes Imaging Agent Production; Shares Rise 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2573939890","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573939890?lang=en_us&edition=fundamental","pubTime":"2025-10-07 12:18","pubTimestamp":1759810692,"startTime":"0","endTime":"0","summary":"Imagion Biosystems  said its contract manufacturer completed production of MagSense, its HER2 breast cancer imaging agent, and is now completing the required analytical testing for use in its phase 2 clinical study, according to a Tuesday filing with the Australian bourse.The company also said the US federal government shutdown will not impact its phase 2 clinical trial investigational new drug application submission.Shares of the company rose 6% in recent Tuesday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IBX.AU","BK7007"],"gpt_icon":0},{"id":"2566941718","title":"ASX Biggest Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2566941718","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566941718?lang=en_us&edition=fundamental","pubTime":"2025-09-12 10:59","pubTimestamp":1757645966,"startTime":"0","endTime":"0","summary":"Here are the 10 ASX-listed companies with the biggest gains on Friday.333D  : +122%, AU$0.175Locksley Resources : +36%, AU$0.49Imagion Biosystems : +29%, AU$0.04Kula Gold : +25%, AU$0.013BSA Ltd : +24%, AU$0.13Bayan Mining and Minerals : +22%, AU$0.195Lumos Diagnostics Holdings : +21%, AU$0.17EV Resources : +21%, AU$0.015Australian Bond Exchange Holdings : +20%, AU$0.036Lightning Minerals : +20%, AU$0.048","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7504","T3D.AU","KGD.AU","LDX.AU","EVR.AU","BMM.AU","BK7007","BK7104","BSA.AU","L1M.AU","BK7064","BK7013","LKY.AU","BK7039","IBX.AU","BK7095","BK7055","ABE.AU","BK7126"],"gpt_icon":0},{"id":"2566926651","title":"ASX Runners of the Week: 333D, Imagion Biosciences, Zenith & Locksley","url":"https://stock-news.laohu8.com/highlight/detail?id=2566926651","media":"The West Australian","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566926651?lang=en_us&edition=fundamental","pubTime":"2025-09-12 07:02","pubTimestamp":1757631724,"startTime":"0","endTime":"0","summary":"Bulls N’ Bears ASX Runner of the Week is… 333D Limited, after the company revealed a new Bitcoin moonshot policy to complement its digital asset management efforts.","market":"us","thumbnail":"https://images.thewest.com.au/publication/C-19999232/f3ba145e5bde0aa97d4b38a2ae55d7e52f82c4d9.jpg","type":0,"news_type":0,"thumbnails":["https://images.thewest.com.au/publication/C-19999232/f3ba145e5bde0aa97d4b38a2ae55d7e52f82c4d9.jpg"],"rights":{"source":"thewest_stock","url":"https://thewest.com.au/business/bulls-n-bears/asx-runners-of-the-week-333d-imagion-biosciences-zenith-locksley-c-19999232","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thewest.com.au/business/bulls-n-bears/asx-runners-of-the-week-333d-imagion-biosciences-zenith-locksley-c-19999232","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thewest_stock","symbols":["BK7013","T3D.AU","ZNC.AU","03008","09439","BK4594","09042","IBX.AU","BK4585","03439","BK4588","BK1611","BK7007","83042","LKY.AU","03042","BK4601","09008","BK7095"],"gpt_icon":1}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}]}}